<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>306</serviceExecutionTime><Drug id="9485"><DrugName>gusperimus trihydrochloride</DrugName><DrugNamesKey><Name id="42759659">Spanidin</Name><Name id="42759660">gusperimus</Name></DrugNamesKey><DrugSynonyms><Name><Value>BMS-181173</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BMY-42215-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>gusperimus trihydrochloride</Value></Name><Name><Value>NKT-01</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NSC-356894</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Spanidin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>gusperimus</Value><Types><Type>INN</Type></Types></Name><Name><Value>DSG</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>deoxyspergualin</Value></Name><Name><Value>gusperimus hydrochloride</Value></Name><Name><Value>85468-01-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>98629-43-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18535">Nippon Kayaku Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1045267">Nordic Group</Company><Company id="20297">Takara Shuzo Co Ltd</Company><Company id="18535">Nippon Kayaku Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="16816">Behringwerke AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9485" type="Drug"><TargetEntity id="90760" type="siDrug">Gusperimus hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1045267" type="Company"><TargetEntity id="5001350224" type="organizationId">Nordic Pharma SAS</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="16816" type="Company"><TargetEntity id="4296487651" type="organizationId">Behringwerke AG</TargetEntity></SourceEntity><SourceEntity id="18535" type="Company"><TargetEntity id="4295876918" type="organizationId">Nippon Kayaku Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20297" type="Company"><TargetEntity id="5000048766" type="organizationId">Takara Shuzo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1888" type="ciIndication"><TargetEntity id="M31.3" type="ICD10"></TargetEntity><TargetEntity id="10047888" type="MEDDRA"></TargetEntity><TargetEntity id="D014890" type="MeSH"></TargetEntity><TargetEntity id="900" type="ORPHANET"></TargetEntity><TargetEntity id="-303927819" type="omicsDisease"></TargetEntity><TargetEntity id="736" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2404" type="ciIndication"><TargetEntity id="10025140" type="MEDDRA"></TargetEntity><TargetEntity id="D008181" type="MeSH"></TargetEntity><TargetEntity id="-329641834" type="omicsDisease"></TargetEntity><TargetEntity id="340" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Transplant rejection - Japan - May-1994</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1888">Wegener granulomatosis</Indication><Indication id="2404">Lupus nephritis</Indication><Indication id="515">Transplant rejection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="213">Multiple sclerosis</Indication><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="8003">Hsp 70 family inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-07T11:35:25.000Z</LastModificationDate><ChangeDateLast>2017-05-16T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18535" linkType="Company"&gt;Nippon Kayaku&lt;/ulink&gt; has developed and launched gusperimus trihydrochloride (Spanidin; NKT-01), as an immunosuppressant and Hsp70 family protein inhibitor, for the prevention of renal transplant rejection; it was launched in Japan for this indication in 1994 [&lt;ulink linkID="518448" linkType="Reference"&gt;518448&lt;/ulink&gt;], [&lt;ulink linkID="1174246" linkType="Reference"&gt;1174246&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Gusperimus is also under development for the potential treatment of lupus nephritis [&lt;ulink linkID="935495" linkType="Reference"&gt;935495&lt;/ulink&gt;], and refractory vasculitis in Wegener's granulomatosis (WG). Nippon's licensee &lt;ulink linkID="1045267" linkType="Company"&gt;Nordic Group&lt;/ulink&gt; is also developing the product for WG relapse [&lt;ulink linkID="1157715" linkType="Reference"&gt;1157715&lt;/ulink&gt;]. In February 2003,  an MAA was filed in the EU for this indication; however, in June 2008, the company withdrew the MAA [&lt;ulink linkID="918822" linkType="Reference"&gt;918822&lt;/ulink&gt;]. An EMA filing was submitted in December 2006 [&lt;ulink linkID="1277627" linkType="Reference"&gt;1277627&lt;/ulink&gt;]. By August 2005, phase II trials were underway in Japan for this indication [&lt;ulink linkID="658789" linkType="Reference"&gt;658789&lt;/ulink&gt;]. In November 2011, a phase III WG relapse study had been initiated [&lt;ulink linkID="1391376" linkType="Reference"&gt;1391376&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound has also previously been developed  by &lt;ulink linkID="16816" linkType="Company"&gt;Behringwerke&lt;/ulink&gt; (Hoechst)  for multiple sclerosis (MS) [&lt;ulink linkID="171539" linkType="reference"&gt;171539&lt;/ulink&gt;], and  by &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) for rheumatoid arthritis (RA) [&lt;ulink linkID="206604" linkType="reference"&gt;206604&lt;/ulink&gt;]. In April 1995, however, Behringwerke announced that it was discontinuing development for MS due to a rejection by the German BfArM of the company's expedited approval application on the basis of results of a second clinical trial in which the drug did not show any clinical benefit [&lt;ulink linkID="176748" linkType="reference"&gt;176748&lt;/ulink&gt;]. BMS was undertaking phase III trials for organ transplantation and phase II trials for RA in the US by December 1995 [&lt;ulink linkID="206604" linkType="reference"&gt;206604&lt;/ulink&gt;]; however, no further development was reported by the company.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2011, the drug was awarded Orphan status for WG [&lt;ulink linkID="1255884" linkType="Reference"&gt;1255884&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Wegener's granulomatosis&lt;/subtitle&gt;In March 2001, EU Orphan Drug designation was granted to Euro Nippon Kayaku for the use of gusperimus in the treatment of Wegener's granulomatosis [&lt;ulink linkID="407690" linkType="reference"&gt;407690&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An NDA was filed in the EU in February 2003 [&lt;ulink linkID="518443" linkType="reference"&gt;518443&lt;/ulink&gt;]; in late 2003, European launch  was expected in fiscal year 2005 [&lt;ulink linkID="518443" linkType="reference"&gt;518443&lt;/ulink&gt;]. In June 2008, the company withdrew its MAA  because the EMEA's CHMP had requested an additional controlled study, which the company did not expect to be able to complete within the timeframe allowed by the centralized procedure [&lt;ulink linkID="918822" linkType="Reference"&gt;918822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Wegener's granulomatosis&lt;/subtitle&gt;By early February 2003, an NDA was being prepared [&lt;ulink linkID="478231" linkType="reference"&gt;478231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal transplant rejection&lt;/subtitle&gt;In 1994, gusperimus was launched for the prevention of renal transplant rejection [&lt;ulink linkID="226144" linkType="reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1174246" linkType="Reference"&gt;1174246&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Wegener's granulomatosis&lt;/subtitle&gt;In November 2011, a randomized, parallel-assignment, open-label, safety and efficacy, phase III trial (&lt;ulink linkID="81374" linkType="Protocol"&gt;NCT01446211&lt;/ulink&gt;; SPARROW; NO005-NK103, 2011-001219-30) to evaluate gusperimus treatment compared with standard treatment in patients with relapse of WG receiving glucocorticoids began in the Czech Republic. The primary endpoint was response rate over 52 weeks. At that time, the trial was expected to complete in April 2014 [&lt;ulink linkID="1391376" linkType="Reference"&gt;1391376&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, it had been reported that a late phase II study had been performed in Europe by the end of 2006 in patients (n = 45) with refractory WG. Gusperimus was self-administered sc (0.5 mg/kg/day) for 21 days followed by a minimum, seven-day rest period, as part of  a 6  cycle treatment period. It was reported that the response rate was 92%, with complete remission in 46% of patients and partial remission in 46% of patients. Reported side effects included reversible leucopenia, neutropenia and anemia; all side effects were manageable and reversible [&lt;ulink linkID="1157715" linkType="Reference"&gt;1157715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2003, phase IIa trials had been completed in Germany [&lt;ulink linkID="478231" linkType="reference"&gt;478231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By the end of 2000,  an early phase II study had been performed in Germany in patients (n = 20) with intractable ANCA-associated vasculitis (19 WG patients and 1 microscopic polyangiitis patient). Gusperimus was administered iv (only in the first week of the first course) or sc  once a day (0.5 mg/kg/day) for 28 days. If the WBC count dropped to 3000 microl during the period, administration was suspended until a least a WBC of 4000 microl was achieved. This was repeated for up to 6 cycles. Improvement was reported in 70% of the cases, and the majority of  patients experienced transient leucopenia of a similar pattern during the study. No mortality or septicemia was observed; mild to moderate infections were also reported [&lt;ulink linkID="1157715" linkType="Reference"&gt;1157715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Lupus nephritis&lt;/subtitle&gt;In October 2003, the company initiated a phase I/II, open-label, uncontrolled, single-group study (&lt;ulink linkID="19452" linkType="Protocol"&gt;NCT00709722&lt;/ulink&gt;; SLE01-ENK). The  trial was conducted in Germany and the Czech Republic, and was to evaluate the safety and efficacy  of the drug in patients (n = 21) with uncontrolled lupus nephritis who were receiving oral corticosteroids  and who had received prior treatment with standard immunosuppressive therapy. Subjects received  14 consecutive days of treatment of sc gusperimus (0.5 mg/kg/day) followed by a 1-week rest, for nine cycles. The primary outcome was complete and partial responses evaluated on the last day of the fourth, sixth and ninth cycles. The trial was completed in April 2007 [&lt;ulink linkID="935495" linkType="Reference"&gt;935495&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The substance was originally discovered at the Tokyo Institute of Microbial Chemistry [&lt;ulink linkID="226144" linkType="reference"&gt;226144&lt;/ulink&gt;]. European development for  Wegener's granulomatosis was carried out by a contract research organization in Germany [&lt;ulink linkID="518443" linkType="Reference"&gt;518443&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Tom W.J. Huizinga, M.D., Ph.D., Department of Rheumatology, &lt;ulink linkType="Company" linkID="21063"&gt;University Hospital&lt;/ulink&gt; Leiden, The Netherlands.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;20th November 1996&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Heat shock proteins bind to other proteins in order to enable correct folding or to modulate the function of other intracellular proteins. &lt;ulink linkType="Drug" linkID="9485"&gt;Gusperimus trihydrochloride&lt;/ulink&gt; interacts with the heat shock protein Hsc 70 (the constitutive form of Hsp 70) at its C-terminus [&lt;ulink linkType="reference" linkID="198301"&gt;198301&lt;/ulink&gt;]. This binding inhibits the translocation of Hsc 70 to the nucleus [&lt;ulink linkType="reference" linkID="195913"&gt;195913&lt;/ulink&gt;], with a simultaneous &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt;-induced dose-dependent reduction in the amount of the transcription factor nuclear factor kappa B (NFkB) being observed [&lt;ulink linkType="reference" linkID="195913"&gt;195913&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt;-induced inhibition of NFkB nuclear translocation has been shown in a B-cell line [&lt;ulink linkType="reference" linkID="198309"&gt;198309&lt;/ulink&gt;], which resulted in a greater than 80% inhibition of surface IgM. This was probably induced by a 10-fold reduction in kappa-light chain mRNA expression. Also in T-cells, the differentiation from the CD4-CD8- double negatives to the CD4+CD8+ double positives was blocked by &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="218720"&gt;218720&lt;/ulink&gt;]. In several animal models in which autoantibody-titers are known to rise during the disease flare, &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; was effective in reducing the level of circulating autoantibodies [&lt;ulink linkType="reference" linkID="198306"&gt;198306&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="218738"&gt;218738&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="222728"&gt;222728&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="222733"&gt;222733&lt;/ulink&gt;].&lt;br/&gt;In several animal models of arthritis, including adjuvant arthritis in rats and collagen-induced arthritis in rats and mice, &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; was effective in preventing the disease onset as well as reducing the established disease [&lt;ulink linkType="reference" linkID="222733"&gt;222733&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="222728"&gt;222728&lt;/ulink&gt;]. Similarly, in MRL mice, which spontaneously develop arthritis, &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; inhibited the development of the disease [&lt;ulink linkType="reference" linkID="222728"&gt;222728&lt;/ulink&gt;]. Moreover, in MRL mice, other clinical and serological features of the autoimmune process were also inhibited [&lt;ulink linkType="reference" linkID="222729"&gt;222729&lt;/ulink&gt;]. In several other models of auto- and allo-immune mediated diseases such as diabetes and kidney transplantation gusperimus trihychloride was effective in either preventing or  reducing the severity of the disease [&lt;ulink linkType="reference" linkID="218739"&gt;218739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism/Toxicity&lt;/subtitle&gt;Pharmacokinetic studies have been reported on the intravenous administration of &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; at doses in the range of 80 to 2792 mg/m2 [&lt;ulink linkType="reference" linkID="214536"&gt;214536&lt;/ulink&gt;]. The average plasma concentration ranged from 0.07 - 7 microg/ml, with a plasma half-life of 1.9 h. The mean total body clearance was 25 l/h/m2. The dose limiting toxicity was reversible hypotension and appeared with plasma levels greater than 4 microg/ml. Toxicity has been reported in a phase II study in cancer patients, with neuromuscular side-effects (myalgias, paresthesias) and granulocytopenia as the most important ones [&lt;ulink linkType="reference" linkID="222768"&gt;222768&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II-trials&lt;/subtitle&gt;In rheumatoid arthritis or systemic lupus erythematosus, no phase I or phase II trials have been reported. However in cancer (refractory solid tumors), a phase I study was performed that showed minimal toxicity but minimal efficacy as measured by LAK-activity. An intriguing phase I study was performed in patients who had received a mouse monoclonal antibody [&lt;ulink linkType="reference" linkID="222756"&gt;222756&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="9485"&gt;Gusperimus trihydrochloride&lt;/ulink&gt; was administered at doses ranging from 50 - 150 mg/m2 and was shown to suppress the human-anti-mouse antibody response with virtually no toxicity. A phase II trial in metastatic breast cancer patients failed to find any evidence of immunosuppression or anti-cancer effects [&lt;ulink linkType="reference" linkID="222768"&gt;222768&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CURRENT OPINION&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="9485"&gt;Gusperimus trihydrochloride&lt;/ulink&gt; was launched in Japan for use in renal transplantation. Given the effect on B-cell immunity and presumably on T-cell differentiation, as well as the beneficial effects on animal models of rheumatoid arthritis, one might expect some efficacy in the human condition.&lt;br/&gt;The marketplace of &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; will be one of the so-called 'disease modifying anti-rheumatic drugs' (DMARDs) such as gold, methotrexate, &lt;ulink linkType="Drug" linkID="46933"&gt;sulphasalazine&lt;/ulink&gt;, azathioprine, anti-malarials, D-penicillamine and probably cyclosporin. Since &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; is the only one of these drugs to have a profound effect on B-cell function, the drug is probably going to be most effective in combination with one of the other DMARDs. However, the clinical trial design will be more difficult and the potential market smaller, as monotherapy with &lt;ulink linkType="Drug" linkID="9485"&gt;gusperimus trihydrochloride&lt;/ulink&gt; is probably more effective in a disease with a more profound disregulation of B-cell immunity such as systemic lupus erythematosus. If the side effect profile is as beneficial as reported then this drug might prove to be a valuable agent in a wide array of diseases in which a disregulation of B-cell function is involved in the pathogenesis.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20297">Takara Shuzo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-05-03T00:00:00.000Z</StatusDate><Source id="176916" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-05-03T00:00:00.000Z</StatusDate><Source id="176916" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-08T00:00:00.000Z</StatusDate><Source id="1277627" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045267">Nordic Group</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-30T00:00:00.000Z</StatusDate><Source id="1391376" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2404">Lupus nephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-30T00:00:00.000Z</StatusDate><Source id="935495" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-08-20T00:00:00.000Z</StatusDate><Source id="658789" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045267">Nordic Group</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-20T00:00:00.000Z</StatusDate><Source id="1157715" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2404">Lupus nephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-30T00:00:00.000Z</StatusDate><Source id="935495" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16816">Behringwerke AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="176748" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-04-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-02-03T00:00:00.000Z</StatusDate><Source id="478231" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-04-16T00:00:00.000Z</StatusDate><Source id="204704" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-01T00:00:00.000Z</StatusDate><Source id="407690" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-04-16T00:00:00.000Z</StatusDate><Source id="204704" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-05-03T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="176748" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-02-28T00:00:00.000Z</StatusDate><Source id="518443" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18535">Nippon Kayaku Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1888">Wegener granulomatosis</Indication><AwardedIndication>Treatment of Wegener’s granulomatosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1045267">Nordic Group</OwnerCompany><Country id="US">US</Country><Indication id="1888">Wegener granulomatosis</Indication><AwardedIndication>Treatment of Wegener's granulomatosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-29T00:00:00.000Z</MileStoneDate><Source id="1255884" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18535">Nippon Kayaku Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1888">Wegener granulomatosis</Indication><AwardedIndication>Treatment of Wegener’s granulomatosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-02T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18535">Nippon Kayaku Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1888">Wegener granulomatosis</Indication><AwardedIndication>Treatment of Wegener’s granulomatosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-03-29T00:00:00.000Z</MileStoneDate><Source id="407690" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15065">Bristol-Myers Squibb Co</OwnerCompany><Country id="US">US</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>Treatment of acute renal graft rejection episodes.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-27T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00952"><Name>Hsp 70 family</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1045267">Nordic Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18535">Nippon Kayaku Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C(CCCNC(=N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O</Smiles><Smiles>C(CCCNC(=N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O.Cl.Cl.Cl</Smiles></StructureSmiles><Deals><Deal id="119921" title="Bristol-Myers Squibb to develop Nippon Kayaku's gusperimus trihydrochloride in North America "></Deal><Deal id="119923" title="Behringwerke to develop Nippon Kayaku's gusperimus trihydrochloride "></Deal><Deal id="133395" title="Nordic Group to develop and commercialize Nippon Kayaku's Spanidin in selected territories outside of Japan and Europe"></Deal></Deals><PatentFamilies><PatentFamily id="1235009" number="WO-00071103" title="Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases"></PatentFamily><PatentFamily id="2159118" number="EP-00094632" title="(-)-15-Deoxyspergualin, A Process For The Preparation Of The Same, An Intermediate Of The Same, And Its Use As Medicament"></PatentFamily><PatentFamily id="237701" number="US-04518532" title="N-(4-(3-Aminopropyl)-aminobutyl)-2-((omega)-guanidino-fatty-acid-amido)-2-substituted-ethanamide and salt thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nordic Group" id="1045267"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Microbial Chemistry Research Foundation" id="14851"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Kayaku Co Ltd" id="18535"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Heidelberg" id="28348"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takara Holdings Inc" id="30651"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>